Natera publishes new clinical validation of Signatera for lymphoma MRD
Natera said new data published in Blood Neoplasia validates the prognostic and predictive value of Signatera for MRD assessment in newly diagnosed and relapsed/refractory lymphoma patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.